Florida Law Preserves Podiatrists' Access to Cellular or Tissue-Based Products (CTP)

APMA congratulates the Florida Podiatric Medical Association (FPMA) on the enactment of legislation, SB 1092, that preserves podiatric physicians' ability to utilize certain cellular or tissue-based products (including skin substitutes) not approved by the Food and Drug Administration (FDA) within their scope of practice.

The legislation addresses concerns created by a 2025 law that authorized only MDs and DOs to provide these therapies, potentially excluding podiatric physicians from offering treatments they have historically provided within the foot and ankle. The new law ensures podiatric physicians remain eligible to perform these procedures, subject to specified education, consent, and safety requirements.

APMA worked closely with FPMA throughout the legislative process and provided advocacy support to help advance the legislation. The change helps maintain patient access to foot and ankle care, supports continuity of care for patients, and preserves podiatrists' ability to utilize cellular and tissue-based products. The law takes effect July 1.